Rutherford Cross retained by Kelso Pharma to appoint a Financial Analyst

Kelso Pharma’s vision is to bring innovative, value-added, specialty medicines to the European healthcare markets. These medicines provide meaningful benefits to patients and create added value for healthcare stakeholders. Kelso Pharma is built upon a blend of company & product acquisitions, partnerships and organic growth, both in the UK and in Europe. The business is focused on creating a positive, entrepreneurial working environment for its people – because a happy team creates value for patients, the healthcare system and the business.

The company is backed by Apposite Capital LLP, a private equity firm specialising in investing in SME businesses in healthcare. The Kelso Pharma team has extensive experience in growing and running a specialty pharma business across Europe

As a result of the recent acquisition and the ambitious growth plans to develop the group into a pan-European specialty healthcare business, the demands on the finance function are increasing. The business now requires a greater level of MI to support strategic decision-making.

The newly created Financial Analyst post will support the Chief Financial Officer by helping to deliver the operational finance needs of the business, as well as supporting the processes, data capture and reporting changes necessary to facilitate the coming growth acceleration.

This is an exciting, progressive opportunity for a talented finance professional with the desire to join a high-growth and innovative company. It is crucial that the appointed candidate is able to build positive relationships with key stakeholders across the business to ensure a long-term fit within the relatively small team.

For more information on this exciting career opportunity please click here or contact Gillian O’Neil

Mobile: 07432 482 882

Email: [email protected]